1.9401

2.02% -0.0399

Bluejay Diagnostics Inc (BJDX)

Überblick Nachrichten Preisverlauf Financials Warum fällt BJDX? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$1.98

Offen:

$1.9779

24-Stunden-Volumen:

2,151

Relative Volume:

0.01

Marktkapitalisierung:

$1.92M

Einnahmen:

Nettoeinkommen (Verlust:

$-6.85M

KGV:

-0.1257

EPS:

-15.4314

Netto-Cashflow:

$-6.23M

1W Leistung:

+4.31%

1M Leistung:

-27.34%

6M Leistung:

-69.11%

1J Leistung:

-87.81%

1-Tages-Spanne:

$1.9779

1-Wochen-Bereich:

$1.70

$2.05

52-Wochen-Spanne:

$1.70

$40.80

Bluejay Diagnostics Inc Stock (BJDX) Company Profile

Firmenname

Bluejay Diagnostics Inc

Sektor

Healthcare (1118)

Branche

Medical Devices (143)

Telefon

(978) 631-0152

Adresse

360 MASSACHUSETTS AVENUE, SUITE 203, ACTON

Mitarbeiter

Twitter

Nächster Verdiensttermin

Neueste SEC-Einreichungen

BJDX's Discussions on Twitter

Compare BJDX vs ABT, SYK, MDT, BSX, EW

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BJDX Bluejay Diagnostics Inc	1.9779	1.92M	0	-6.85M	-6.23M	-15.43
ABT Abbott Laboratories	107.94	187.91B	44.33B	6.50B	7.40B	3.717
SYK Stryker Corp	339.55	129.05B	25.12B	3.25B	4.28B	8.3984
MDT Medtronic Plc	87.51	112.19B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	68.68	101.72B	20.08B	2.89B	3.66B	1.9391
EW Edwards Lifesciences Corp	82.23	49.14B	6.07B	1.06B	1.34B	1.8063

Bluejay Diagnostics Inc Aktie (BJDX) Neueste Nachrichten

Mar 12, 2026

Bluejay Advances Symphony IL-6 Sepsis Diagnostic Program - TipRanks

Mar 12, 2026

Bluejay Diagnostics: SYMON-I IL-6 Findings Accepted for SAEM 2026 Presentation - TradingView

Mar 12, 2026

Bluejay Diagnostics to Present Findings on IL-6 as a Biomarker for Sepsis at 2026 SAEM Annual Meeting - Quiver Quantitative

Mar 12, 2026

Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting - Bitget

Mar 12, 2026

Study explores link between ER inflammation marker and organ damage in sepsis - Stock Titan

Mar 12, 2026

Mar 11, 2026

Northstrive Fund II has sent a letter to the Board of Directors of Bluejay Diagnostics Inc, recommending that they carefully evaluate a potential acquisition opportunity. - Bitget

Mar 11, 2026

NorthStrive Fund II LP Issues Open Letter to the Board and Shareholders of Bluejay Diagnostics - The Manila Times

Mar 11, 2026

Braeden Lichti Pushes for Changes at Bluejay Diagnostics with 3.65% Stake - TradingView

Mar 11, 2026

Mar 09, 2026

Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook - marketscreener.com

Mar 09, 2026

Mar 06, 2026

Aug Opening: Is Bluejay Diagnostics Inc a good ESG investmentMarket Sentiment Report & Technical Pattern Based Buy Signals - baoquankhu1.vn

Mar 06, 2026

Bluejay 10-K: Net loss $6.85M, operating loss $6.95M; cash through Q3 2026 - TradingView

Mar 06, 2026

Medical diagnostics company Bluejay Diagnostics Inc (stock code: BJDX) is facing financial pressure. According to the company's latest disclosed financial plan, in order to maintain normal operations and advance R&D projects, it must secure at least $20 milli - Bitget

Mar 06, 2026

Bluejay Diagnostics says SYMON II study ‘progressing as planned’ - TipRanks

Mar 06, 2026

Bluejay’s 20-minute sepsis test drives 2026 plan and $20M cash goal - Stock Titan

Mar 06, 2026

Mar 02, 2026

Why is Bluejay Diagnostics Inc. stock going downWeekly Trade Summary & Reliable Momentum Entry Alerts - mfd.ru

Feb 21, 2026

Feb 20, 2026

Bluejay Diagnostics Completes Warrant Exercises, Clarifies Capital Structure - TipRanks

Feb 20, 2026

Bluejay Diagnostics says all prefunded warrants exercised; ~972,000 shares outstanding, 1.5M cash-exercise warrants - TradingView

Feb 20, 2026

Bluejay Diagnostics’ Clinical Study Marks Key Transition from Enrollment to Data Analysis - StocksToTrade

Feb 20, 2026

Prefunded warrants fully exercised at Bluejay Diagnostics (NASDAQ: BJDX) - Stock Titan

Feb 20, 2026

Bluejay Diagnostics completes prefunded warrant exercises By Investing.com - Investing.com Canada

Feb 20, 2026

Bluejay Diagnostics Announces Full Exercise of Prefunded Warrants and Current Share Structure Update - Quiver Quantitative

Feb 20, 2026

Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised - marketscreener.com

Feb 20, 2026

Medical diagnostics firm ends prefunded warrants, flags 13G share confusion - Stock Titan

Feb 20, 2026

Feb 19, 2026

Why Etsy Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - Benzinga

Feb 19, 2026

Feb 18, 2026

Bluejay Advances SYMON II Sepsis Study and Manufacturing - TipRanks

Feb 18, 2026

Bluejay Diagnostics enrolls 545 patients in SYMON II study - TipRanks

Feb 18, 2026

Feb 17, 2026

Bluejay Diagnostics successfully enrolls 545 patients in Symon(TM) II study and advances manufacturing readiness into 2026 - marketscreener.com

Feb 17, 2026

Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026 - The Manila Times

Feb 17, 2026

Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON II Study and Advances Manufacturing Readiness into 2026 - Bitget

Feb 17, 2026

Bluejay Diagnostics Successfully Enrolls 545 Patients In Symon™ Ii Study And Advances Manufacturing Readiness Into 2026 - TradingView

Feb 17, 2026

Bluejay Diagnostics, Inc. Successfully Enrolls 545 Patients in SYMON?? II Study and Advances Manufacturing Readiness into 2026 - marketscreener.com

Feb 17, 2026

Sepsis test maker builds supply for 10M rapid kits as key trial advances - Stock Titan

Feb 17, 2026

Is Bluejay Diagnostics Inc. stock a smart retirement pickTrade Exit Summary & Entry Point Confirmation Signals - mfd.ru

Feb 17, 2026

Feb 16, 2026

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Sees Large Increase in Short Interest - Defense World

Feb 16, 2026

Feb 15, 2026

Block Trades: How does Bluejay Diagnostics Inc score in quality rankings2025 Key Highlights & AI Driven Price Predictions - baoquankhu1.vn

Feb 15, 2026

Feb 13, 2026